The management of metastatic prostate cancer(mPCa)has changed over the past ten years.Several new drugs have been approved with significant overall survival benefits in metastatic castration resistant prostate cancer(PCa)including chemotherapy(docetaxel,cabazitaxel),new hormonal therapies(abiraterone,...
Prostate cancer cells. Credit: NIH Image Gallery Survival rates for men with metastatic prostate cancer have increased by an average of six months, something which coincides with the gradual introduction of "dual treatment" since 2016. This is according to a register study of all Swedish men diag...
These drugs contain radioactive elements that target cancer cells. Doctors tend to use this systemic treatment when the metastasis is stimulating new bone growth. This is more common withprostate cancer. If your cancer has spread to many bones, these drugs may be a better option than standardrad...
Metastatic prostate cancer is considered to be incurable. But now a pilot trial, in 20 selected men with early-stage metastatic prostate cancer, has shown that aggressive multimodality treatment with hormone therapy, surgery, and radiation "can eliminate detectable disease." Overall, 20% of the ...
Patients who want to finish their treatment quickly may prefer docetaxel, said Morris. The second consideration is financial, "depending on the healthcare system in which you are receiving your care." He explained: "For patients who don't have drug coverage, the chemotherapy option could be qui...
different types ofadvanced immunotherapies moving beyond the scope of pd-1, pd-l1, or ctla-4 inhibitors and other smart drugs. advanced immunotherapy for prostate cancer studies indicate how immunotherapy can be optimized in prostate cancer treatment with combinationtherapies which can change the "...
(B·ARGO) and the Urologic Tumors Unit of the Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research Institute (IGTP) have found a new therapeutic strategy for patients with a specific subtype of metastatic prostate cancer resistant to standard chemotherapy treatment with ...
Treatment options for metastatic castration resistant prostate cancer (mCRPC) have expanded rapidly in recent years. Given the significant economic burden, we sought perform a cost-effectiveness analysis (CEA) of the contemporary treatment paradigm for mCRPC. We devised a treatment protocol consisting of...
Metastatic prostate cancer patients present in two ways—with already disseminated disease at the time of presentation or with disease recurrence after definitive local therapy. Androgen deprivation therapy is given as the most effective initial treatment to patients. However, after the initial response,...
If I am using one of these drugs upfront, will my next treatment work when the patient eventually develops castration-resistant prostate cancer? What about short-term (mostly with docetaxel) and long-term (mostly with abiraterone) side effects?